Normocapnia

Normocapnia, in the context of the COMET-AIS clinical trial (NCT04121442) led by the University Hospital, Clermont-Ferrand, refers to a controlled physiological intervention used during general anesthesia for patients undergoing mechanical thrombectomy for acute ischemic stroke. The protocol involves the precise maintenance of arterial carbon dioxide tension (PaCO2) at a standard physiological level of approximately 40 mmHg via mechanical ventilation. This intervention serves as the comparator arm to evaluate the therapeutic potential of moderate hypercapnia (PaCO2 50 mmHg). Carbon dioxide is a potent regulator of cerebral vascular resistance; while hypercapnia is hypothesized to induce vasodilation and enhance collateral blood flow to the ischemic penumbra, normocapnia maintains baseline physiological vascular tone. The study aims to determine if modulating CO2 levels can improve clinical outcomes and reduce infarct progression during the critical period before vessel reperfusion.

Other names

Normocapnia-University Hospital, Clermont-FerrandPaCO2 40mmHgPaCO-2 40mmHgPaCO 2 40mmHgControlled normocapnia